Laurus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LAURUS
LAURUS has twenty-two approved drugs.
There are eight tentative approvals on LAURUS drugs.
Summary for Laurus
| US Patents: | 0 |
| Tradenames: | 18 |
| Ingredients: | 18 |
| NDAs: | 22 |
| Patent Litigation for Laurus: | See patent lawsuits for Laurus |
Drugs and US Patents for Laurus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Laurus | PIRFENIDONE | pirfenidone | TABLET;ORAL | 212722-003 | Jul 19, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 218565-002 | May 1, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | METFORMIN HYDROCHLORIDE | metformin hydrochloride | TABLET;ORAL | 209882-003 | Aug 27, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | VALSARTAN | valsartan | TABLET;ORAL | 218897-003 | Apr 21, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | METFORMIN HYDROCHLORIDE | metformin hydrochloride | TABLET;ORAL | 209882-002 | Aug 27, 2018 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | PIRFENIDONE | pirfenidone | TABLET;ORAL | 212722-001 | Jul 19, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Laurus | GABAPENTIN | gabapentin | CAPSULE;ORAL | 217546-003 | May 12, 2023 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

